deltatrials
Terminated PHASE3 NCT00120796

Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Conditions Hepatitis B
Interventions Lamivudine Recombinant hepatitis B surface antigen
Updated 6 times since 2017 Last updated: Jul 20, 2016 Started: Aug 31, 2005 Primary completion: Jul 31, 2008 Completion: Jul 31, 2008

A PHASE3 clinical study on Hepatitis B, this trial is terminated or withdrawn. The trial is conducted by French National Agency for Research on AIDS and Viral Hepatitis and has accumulated 6 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Oct 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Oct 2021 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • French National Agency for Research on AIDS and Viral Hepatitis
  • GlaxoSmithKline
Data source: ANRS, Emerging Infectious Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Dakar, Senegal